At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 303 enrolled
Drug / intervention
Matching Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Cold Sore Treatments on UV Induced Cold Sores
In Brief
A Phase 2 clinical trial evaluating Matching Placebo and BTL-TML-HSV for Oral Herpes Simplex. Completed, enrolled 303 participants across 3 sites.
Detailed Summary
The purpose of this study is to determine if a new drug treatment is effective to block the development of a cold sore lesion following Ultra Violet (UV) exposure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOral Herpes Simplex
CountriesUnited States
CollaboratorsNorwich Clinical Research Associates Ltd., Hill Top Research
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJul 2013
First PostedJul 2013
Primary CompletionSep 2014
Study CompletionFeb 2015
TodayJul 2026
First PostedJul 18, 2013
Enrollment StartJul 1, 2013
Primary CompletionSep 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 13.0 years ago
Interventions
Matching Placebodrug
Sublingual micro dosing of placebo for 7 days
BTL-TML-HSVdrug
Sublingual micro dosing of BTL-TML-HSV for 7 days